Health Canada's Foreign Action Notification List: 41 Authorities Cut to 22 by 1 October 2026

On 1 October 2026, Health Canada shrinks the list of foreign regulatory authorities whose actions you must report. The list of specified authorities incorporated into section C.01.050 of the Food and Drug Regulations drops from 41 authorities across 35 jurisdictions to 22 authorities across 13 jurisdictions. The 72 hour reporting clock does not change. What changes is which regulators you must watch, and every pharmacovigilance procedure that names the old list is out of date on that date.

If you hold a Drug Identification Number (DIN) or a Notice of Compliance (NOC) in Canada, this is a small regulatory change with a large operational tail. Your foreign action monitoring matrix, your signal intake procedure and your standard operating procedures all reference a list that will no longer be current. This article, written for pharmaceutical market authorization holders, explains exactly what changed, what stayed the same and the short, practical set of steps to take before an inspector asks to see your updated procedure.

Executive summary

In short: Health Canada is replacing its 2018 approach to notifying foreign actions, effective 1 October 2026, and cutting the incorporated list of specified foreign regulatory authorities from 41 to 22. Most European Union and European Economic Area national agencies drop off, because the European Medicines Agency remains the reportable European authority. Japan's entry changes from an agriculture ministry to its human drug regulators. The obligation itself, the 72 hour deadline and the underlying regulation are unchanged.

• The specified list shrinks from 41 authorities across 35 jurisdictions to 22 authorities across 13, in force 1 October 2026.
• The change is framed as red tape reduction and follows a 2025 consultation that drew 184 comments.
• Japan moves from the Ministry of Agriculture, Forestry and Fisheries to the Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA).
• Germany and the Netherlands gain authorities, while most other EU and EEA national agencies come off the list.
• The 72 hour notification deadline under section C.01.050 does not change, and you must still prepare and retain the underlying assessment.

What is the foreign action notification requirement?

The foreign action notification requirement makes market authorization holders (MAHs) tell Health Canada, within 72 hours, when a specified foreign regulator takes action about a serious risk of injury to human health for a drug they also sell in Canada. It is set out in subsections C.01.050(2)(a), (b) and (c) and C.01.050(3) of the Food and Drug Regulations and puts a safety provision of Vanessa's Law into operation.

The rule exists because many drugs are marketed earlier, or in larger volumes, in other countries, so important safety signals are often detected first in a foreign jurisdiction. Notifying Health Canada early lets it assess and mitigate risks to people in Canada across a product's life cycle. The provision operationalizes the Protecting Canadians from Unsafe Drugs Act, better known as Vanessa's Law, which received Royal Assent on 6 November 2014. The enabling regulations were published in the Canada Gazette, Part II, on 2 May 2018.

The requirement applies to three classes of drugs that carry a DIN or a NOC: prescription drugs; drugs required to be sold under a prescription by Part G of the Food and Drug Regulations, the Benzodiazepines and Other Targeted Substances Regulations or the Narcotic Control Regulations; and drugs permitted to be sold without a prescription but administered only under the supervision of a practitioner. It covers both human and veterinary drugs when the foreign action concerns a serious risk of injury to human health. It does not apply to drugs still under review for market authorization.

What changes on 1 October 2026?

Health Canada is replacing the 2018 guidance and the list of specified authorities incorporated by reference. The list falls from 41 authorities across 35 jurisdictions to 22 authorities across 13. Health Canada describes this as reducing the authorities by more than half. That statement is fully accurate for jurisdictions, which drop from 35 to 13, a cut of about 63 per cent, and close for authorities, which drop from 41 to 22, a cut of about 46 per cent. When you write about the change internally, the safest phrasing is precise: from 41 authorities across 35 jurisdictions to 22 across 13.

The numbers, verified

The specified list has three parts: Part A for risk communications, Part B for label changes and Part C for recalls, reassessments and suspensions or revocations of market authorization. On the new list, Parts A, B and C are identical, each naming the same 22 authorities. One publication hazard is worth flagging: the new list page is labelled Draft in its title, yet it carries a hard 1 October 2026 in force date and is incorporated by reference into the regulations. Treat it as effective on that date, not as an optional draft.

Which jurisdictions drop off

The single biggest driver of the cut is Europe. Because the European Medicines Agency remains the reportable European authority, most EU and EEA national agencies come off the list. Agencies such as Spain's AEMPS, Sweden's Medical Products Agency, Portugal's INFARMED, the Czech SUKL, Finland's Fimea and Norway's NoMA are all removed. If your monitoring matrix currently lists those national agencies as separate triggers, you can stop monitoring them as of 1 October, provided you continue to monitor the European Medicines Agency.

Japan, Germany and the Netherlands: the substantive changes

A few jurisdictions actually deepen. Japan's entry changes from the Ministry of Agriculture, Forestry and Fisheries, a veterinary and agriculture body, to the Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA). In practice, Japan moves from a narrow veterinary trigger to its full human drug regulators, so a MAH with Japanese products may need to monitor more, not less. Germany expands from three authorities to five, adding the Federal Institute for Drugs and Medical Devices (BfArM) and the Paul Ehrlich Institute. The Netherlands adds the Medicines Evaluation Board alongside its health care inspectorate. New Zealand also gains a second authority. The lesson is that a shorter overall list does not mean a lighter load for every product.

What does not change, and where firms get caught

The obligation itself, the 72 hour clock and the requirement to prepare and retain your assessment are all unchanged. The most common misreading is to treat a shorter list as less work. You still monitor, assess, document and, where the seriousness threshold is met, report within 72 hours of receiving or becoming aware of the information. A qualified person for the MAH must decide whether the risk meets the threshold.

There is a documentation trap here. Removing an authority from your monitoring matrix is not the same as deleting the evidence that you monitored it while it was in scope. Health Canada may assess your ability to monitor and report foreign actions during an inspection, and can verify compliance by checking your incoming reports against its own environmental scans. A clean, dated change record showing when and why you revised the matrix is exactly the kind of artefact that holds up during an inspection. A separate hazard is that the older guidance still hyperlinks to the previous list, so anyone following its own links after 1 October could land on a superseded instrument. Re-point every internal reference to the current list.

Compliance checklist

• Pull your current foreign action monitoring matrix and map every listed authority against the new 22 authority list.
• Remove the 22 dropped jurisdictions from active monitoring on 1 October 2026, while keeping the change record and rationale.
• Add or update the deepened entries: MHLW and PMDA for Japan, BfArM and the Paul Ehrlich Institute for Germany, the Medicines Evaluation Board for the Netherlands.
• Re-point every SOP, work instruction and matrix reference away from the 2018 list and toward the current list.
• Confirm your signal intake procedure still triggers a 72 hour notification and names the current forms and submission route.
• Retrain qualified persons and pharmacovigilance staff, and document the training so it can be shown at inspection.
• Keep monitoring and retaining the underlying assessment for every product, even where an authority has been removed.

Common mistakes

• Reading a shorter list as licence to reduce pharmacovigilance effort. The monitoring, assessment and 72 hour reporting duties are unchanged.
• Assuming every jurisdiction shrank. Japan, Germany, the Netherlands and New Zealand gained or changed authorities.
• Deleting monitoring evidence when you remove an authority, rather than keeping a dated change record.
• Leaving SOPs pointed at the 2018 list, so staff follow a stale hyperlink to a superseded instrument.
• Treating the new list as an optional draft because of its Draft label, even though it has a fixed 1 October in force date.

Frequently asked questions

How many days do I have to notify Health Canada of a foreign action?

You have 72 hours after you receive or become aware of information that concerns a serious risk of injury to human health and is associated with a specified foreign action. This deadline is set by subsection C.01.050(3) and does not change on 1 October 2026.

Do I still have to report actions by EU national agencies after 1 October 2026?

For most EU and EEA member states, no. Those national agencies are removed from the specified list, because the European Medicines Agency remains the reportable European authority. France, Germany, the Netherlands, Ireland and Italy are exceptions that keep national authorities on the list. You may still voluntarily notify Health Canada of an action by a country that is not listed, and it welcomes that information for safety monitoring.

Why did Japan's entry change?

The old list named the Ministry of Agriculture, Forestry and Fisheries, an agriculture and veterinary body. The new list names the Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA), Japan's human drug regulators. For a MAH with Japanese products, this can expand the scope of relevant actions rather than reduce it.

Does the reduced list mean less pharmacovigilance work?

No. You still need to monitor the specified authorities, assess whether an action meets the serious risk threshold, document your decisions and report within 72 hours when it does. The change reduces the number of authorities to watch, not the quality of the process behind the watching.

What is the difference between this and Health Canada's foreign reliance order?

They are different mechanisms. Foreign action notification is a post-market safety duty: you tell Health Canada when a foreign regulator acts on a serious risk. The Ministerial reliance order is a pre-market pathway that lets Health Canada rely on decisions or documents from certain foreign regulators to speed a review. One is about ongoing safety, the other about market entry.

When exactly does the new list take effect?

The revised guidance and the new 22 authority list come into effect on 1 October 2026. Until then, the current 41 authority list applies. Any procedure that references the old list should be updated to take effect on the same date.

How MFLRC can help

MFLRC works with market authorization holders on exactly this kind of dated, procedural change. We run a pharmacovigilance procedure gap assessment against the new 22 authority list, rebuild your foreign action monitoring matrix, and update the regulatory affairs and quality SOPs that reference it. Our team includes a Health Canada security cleared, approved Quality Assurance Person, so the advice is senior, practical and defensible. We can also deliver the MAH training and change records that inspectors expect to see.

Your foreign action monitoring list changes on 1 October. We will review your pharmacovigilance SOP against the new 22 authority list and tell you exactly which procedures need rewriting, before the date, not after an inspection.

Conclusion

The foreign action list change is a good example of a compliance obligation that looks minor on paper and is real work in practice. The rule and the 72 hour clock stay the same, but the specified authorities move, and every procedure that names them needs to move with them by 1 October 2026. MAHs that already run tight drug shortage and recall reporting processes will find this a quick update. The ones caught out will be those whose matrices still point at a list that no longer exists. Update it now, keep the change record, and you turn a deadline into a non-event.

Sources and references

• Health Canada, Guidance on notifying Health Canada of foreign actions
• Health Canada, Draft list of regulatory authorities for notifying Health Canada of foreign actions (in force 1 October 2026)
• Health Canada, List of Regulatory Authorities for Purposes of Section C.01.050 (current 41 authority list)
• Justice Laws, Food and Drug Regulations, section C.01.050
• Health Canada, Protecting Canadians from Unsafe Drugs Act (Vanessa's Law), questions and answers